ArQule Inc. (ARQL) and Dare Bioscience Inc. (NASDAQ:DARE) Contrasting side by side

ArQule Inc. (NASDAQ:ARQL) and Dare Bioscience Inc. (NASDAQ:DARE) have been rivals in the Biotechnology for quite some time. Below is a review of each business including various aspects such as risk, analyst recommendations, institutional ownership, profitability, dividends, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ArQule Inc. 22.82M 15.90 14.76M -0.17 0.00
Dare Bioscience Inc. N/A 0.00 22.95M -2.92 0.00

Table 1 demonstrates ArQule Inc. and Dare Bioscience Inc.’s top-line revenue, earnings per share (EPS) and valuation.


Table 2 shows us the return on assets, return on equity and net margins of both companies.

Net Margins Return on Equity Return on Assets
ArQule Inc. -64.68% -42.7% -23%
Dare Bioscience Inc. 0.00% -180.3% -166.4%

Risk and Volatility

ArQule Inc.’s 1.61 beta indicates that its volatility is 61.00% more volatile than that of Standard & Poor’s 500. Competitively, Dare Bioscience Inc.’s 123.00% volatility makes it more volatile than Standard & Poor’s 500, because of the 2.23 beta.


The current Quick Ratio of ArQule Inc. is 9.6 while its Current Ratio is 9.6. Meanwhile, Dare Bioscience Inc. has a Current Ratio of 8.5 while its Quick Ratio is 8.5. ArQule Inc. is better positioned to pay off its short-term and long-term debts than Dare Bioscience Inc.

Insider and Institutional Ownership

Institutional investors owned 85.8% of ArQule Inc. shares and 21.3% of Dare Bioscience Inc. shares. Insiders owned 0.6% of ArQule Inc. shares. Insiders Competitively, owned 1.2% of Dare Bioscience Inc. shares.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
ArQule Inc. -4.31% -11.91% -41.71% -32.77% 133.55% 115.15%
Dare Bioscience Inc. -4.87% -9.89% -18% -44.59% -66.67% -62.11%

For the past year ArQule Inc. had bullish trend while Dare Bioscience Inc. had bearish trend.


ArQule Inc. beats on 8 of the 9 factors Dare Bioscience Inc.

ArQule, Inc., a biopharmaceutical company, researches and develops therapeutics for the treatment of cancer and rare diseases in the United States. Its lead product candidate is tivantinib (ARQ 197), a small molecule inhibitor of the c-Met receptor tyrosine kinase and its biological pathway, which is in Phase III clinical trial for the treatment of liver cancer. The companyÂ’s clinical-stage products include ARQ 087, a multi-kinase inhibitor of the fibroblast growth factor receptor family Phase II clinical trial for patients with intrahepatic cholangiocarcinoma and in Phase Ib for multiple oncology indications; ARQ 092, an inhibitor of the AKT serine/threonine kinase in Phase I clinical trials for multiple oncology indications; ARQ 751, a next-generation inhibitor of AKT in Phase I clinical trial for solid tumors; and ARQ 761, an intravenously administered analogue of Beta-lapachone, which is Phase 1b clinical trial used as a promoter of NQo1-mediated programmed cancer cell death. Its pre-clinical development program also includes ARQ 531, an inhibitor of BrutonÂ’s tyrosine kinase. The company has co-development and co-commercialization agreement with Daiichi Sankyo Co., Ltd.; license agreement with Kyowa Hakko Kirin Co., Ltd.; and collaborative research and development agreement with Beryllium Development Corp. Arqule, Inc. was founded in 1993 and is headquartered in Burlington, Massachusetts.

Daré Bioscience, Inc. develops and commercializes product for women’s reproductive health, Ovaprene. The company was incorporated in 2015 and is based in La Jolla, California.